Data coverage, completeness and provenance for SYNTARA LIMITED in the Stock Market API — Health Care · Drug Manufacturers - Specialty & Generic.
Source date: 2026-10-30T00:30:37. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0185 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0190 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0180 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0180 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0190 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/SNT/prices · Price parameters and adjustment semantics
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Website: https://syntaratx.com.au · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/SNT/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 24 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 24 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 26 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 29 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 28 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/SNT
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/SNT/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/SNT/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/SNT/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/SNT/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/SNT
Free tier — instant API key. Built for AI agents.